Analyst Research

Report Title Price
Provider: Wright Reports
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Depomed Inc Reaffirms FY 2013 Revenue Guidance-Conference Call

Monday, 29 Jul 2013 09:00am EDT 

Depomed Inc reaffirmed fiscal 2013 revenue guidance and expects total revenues of approximately $125 to $135 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $125 million for fiscal 2013. 

Latest Key Developments in Pharmaceuticals

Company Quote

-0.44 -3.28%
11 Jul 2014